29 June 2018 - A recent study examining the potential savings determined that, based on the uptake of available biosimilars in Organisation for Economic Co-operation and Development countries, Canada could save between eight per cent and 43 per cent.

Although Health Canada approved Inflectra, the first biosimilar for Remicade, in 2014 to treat a number of conditions, the drug has had a limited impact on private drug plans so far. 

According to Telus Health, Inflectra represented about 1.5% of total eligible costs and almost four per cent of new claimants in 2017 for the conditions both it and Remicade treat.

Read Benefits Canada article